Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
Authors
Keywords
-
Journal
Pharmaceutics
Volume 14, Issue 1, Pages 83
Publisher
MDPI AG
Online
2021-12-30
DOI
10.3390/pharmaceutics14010083
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity
- (2021) Suah Yang et al. BIOMATERIALS
- Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy
- (2021) Jiwoong Choi et al. ACS Nano
- The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis
- (2021) Jinseong Kim et al. BIOMATERIALS
- 100th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery
- (2020) Huanli Sun et al. ACS Macro Letters
- Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy
- (2020) Man Kyu Shim et al. BIOMATERIALS
- Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
- (2020) Jinseong Kim et al. JOURNAL OF CONTROLLED RELEASE
- Trackable Water-Soluble Prodrug Micelles Capable of Rapid Mitochondrial-Targeting and Alkaline pH-Responsive Drug Release for Highly Improved Anticancer Efficacy
- (2019) Bei-Yu Liu et al. ACS Macro Letters
- Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy
- (2019) Wooram Um et al. BIOMATERIALS
- Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy
- (2018) Man Kyu Shim et al. JOURNAL OF CONTROLLED RELEASE
- Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer
- (2018) Seung Woo Chung et al. BIOMATERIALS
- Aldoxorubicin for the treatment of soft tissue sarcoma
- (2017) Esha Sachdev et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging
- (2016) Man Kyu Shim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Cancer biomarker detection: recent achievements and challenges
- (2015) Li Wu et al. CHEMICAL SOCIETY REVIEWS
- Enzyme-Specific Doxorubicin Drug Beacon as Drug-Resistant Theranostic Molecular Probes
- (2015) Lye Lin Lock et al. ACS Macro Letters
- Carbon nanotubes for delivery of small molecule drugs
- (2013) Bin Sheng Wong et al. ADVANCED DRUG DELIVERY REVIEWS
- Doxorubicin, DNA torsion, and chromatin dynamics
- (2013) Fan Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Impact of albumin on drug delivery — New applications on the horizon
- (2011) Bakheet Elsadek et al. JOURNAL OF CONTROLLED RELEASE
- Tumor delivery of macromolecular drugs based on the EPR effect
- (2010) Vladimir Torchilin ADVANCED DRUG DELIVERY REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started